Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus

Next Previous
X
Search
Trial Profile

A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anifrolumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; Registrational
  • Acronyms TULIP SLE LTE
  • Sponsors AstraZeneca; AstraZeneca AB

    • Most Recent Events

    • 15 Jun 2024 Results of Lupus Low Disease Activity State Attainment and Reduced Glucocorticoid use presented at the 25th Annual Congress of the European League Against Rheumatism
    • 15 Nov 2023 Results reporting long-term outcomes; total and organ-specific disease activity over 4 years presented at the ACR Convergence 2023
    • 15 Nov 2023 Results of post hoc analysis assessing renal outcomes in patients with Systemic Lupus Erythematosus with or without evidence of SLEDAI-2K renal involvement at baseline, were presented at the ACR Convergence 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top